Allergan PLC. (AGN) Director Christopher J. Coughlin Purchases 10,000 Shares
Allergan PLC. (NYSE:AGN) Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, December 5th. The stock was purchased at an average cost of $163.30 per share, for a total transaction of $1,633,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Allergan PLC. (AGN) traded down $3.04 on Tuesday, hitting $166.90. The company’s stock had a trading volume of 3,420,700 shares, compared to its average volume of 2,912,006. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. The firm has a market cap of $55,510.00, a P/E ratio of 11.02, a price-to-earnings-growth ratio of 1.14 and a beta of 1.11. Allergan PLC. has a 1 year low of $166.06 and a 1 year high of $256.80.
Allergan (NYSE:AGN) last released its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.06 by $0.09. The business had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. Allergan’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.32 earnings per share. research analysts expect that Allergan PLC. will post 16.28 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.68%. The ex-dividend date is Thursday, November 16th. Allergan’s payout ratio is currently -12.39%.
Several research firms recently weighed in on AGN. Cantor Fitzgerald set a $191.00 price target on Allergan and gave the company a “hold” rating in a research report on Saturday. Morgan Stanley raised Allergan from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $171.92 to $200.00 in a research report on Wednesday, November 29th. Leerink Swann reissued an “outperform” rating and set a $237.00 price target on shares of Allergan in a research report on Monday, November 27th. Wells Fargo & Company restated an “outperform” rating and issued a $245.00 target price (down previously from $258.00) on shares of Allergan in a research note on Thursday, November 2nd. Finally, Royal Bank Of Canada lowered their target price on Allergan from $250.00 to $221.00 and set an “outperform” rating on the stock in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company. Allergan has a consensus rating of “Buy” and an average price target of $244.47.
A number of institutional investors have recently bought and sold shares of AGN. Edgewood Management LLC raised its position in shares of Allergan by 24.3% in the third quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after buying an additional 869,248 shares in the last quarter. Baupost Group LLC MA raised its position in Allergan by 21.9% during the third quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after purchasing an additional 531,600 shares in the last quarter. Asset Management One Co. Ltd. raised its position in Allergan by 4,852.6% during the third quarter. Asset Management One Co. Ltd. now owns 503,088 shares of the company’s stock valued at $103,108,000 after purchasing an additional 492,930 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Allergan by 2.2% during the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after buying an additional 482,220 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Allergan during the third quarter worth $92,182,000. Institutional investors and hedge funds own 81.34% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Allergan PLC. (AGN) Director Christopher J. Coughlin Purchases 10,000 Shares” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/05/allergan-plc-agn-director-christopher-j-coughlin-purchases-10000-shares.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.